Oliver Baumann

Director Ejecutivo en XLIFE SCIENCES AG .

38 años

Finance

Commercial Services

Health Technology

Perfil

Oliver R.
Baumann is Chief Executive Officer & Director at Xlife Sciences AG since 2020, Chief Executive Officer at Akira Trading GmbH, Chairman at Akira Holding AG, Chairman & General Manager at Veraxa Biotech Holding AG, Director at Pecunia Solutions AG, Director at VERAXA Biotech AG, Director at Axenoll Life Sciences AG, and Co-Managing Director at Xrna.
Biotech GmbH.
Former roles include Chief Executive Officer at Belvoir Wealth Management AG and Co-Managing Director at x-diagnostics GmbH.

Cargos activos de Oliver Baumann

Empresas	Cargo	Inicio
XLIFE SCIENCES AG	Director Ejecutivo	01/07/2019
Pecunia Solutions AG	Director/Miembro de la Junta	-
Axenoll Life Sciences AG	Director/Miembro de la Junta	-
Akira Holding AG	Presidente	-

Todos los cargos activos de Oliver Baumann

Antiguos cargos conocidos de Oliver Baumann.

Empresas	Cargo	Fin
Veraxa Biotech AG Veraxa Biotech AG BiotechnologyHealth Technology Develops antibodies based therapeutics	Director/Miembro de la Junta	-
Belvoir Wealth Management AG Belvoir Wealth Management AG Investment ManagersFinance Provides investment advice	Director Ejecutivo	-

Ver el detalle de la experiencia de Oliver Baumann.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Oliver Baumann.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	6
Belvoir Wealth Management AG Belvoir Wealth Management AG Investment ManagersFinance Provides investment advice	Finance
Pecunia Solutions AG
Xlife Sciences AG Xlife Sciences AG Miscellaneous Commercial ServicesCommercial Services Develops life sciences technologies	Commercial Services
Akira Holding AG
Veraxa Biotech AG Veraxa Biotech AG BiotechnologyHealth Technology Develops antibodies based therapeutics	Health Technology
Axenoll Life Sciences AG